PRADAXA (dabigatran etexilate mesylate)
ORAL ANTICOAGULANTS · PULMONARY THROMBOEMBOLISM ·+4
Boehringer Ingelheim
Drug class
Thrombin Inhibitors (Non-Heparinoid)
Thrombin inhibitors (non-heparinoid), more formally known as direct thrombin inhibitors (DTIs), are an anticoagulant drug class distinct from heparin and heparinoids because they do not rely on endogenous antithrombin to exert their activity. Read more about Thrombin Inhibitors (Non-Heparinoid)
42 drugs in this class 36 manufacturers
Drugs in Thrombin Inhibitors (Non-Heparinoid)
ARGATROBAN
THROMBIN INHIBITORS (NON-HEPARINOID) · THROMBOSIS IN HEPARIN-INDUCED THROMBOCYTOPENIA ·+2
PAR HEALTH USA,
BIVALIRUDIN
THROMBIN INHIBITORS (NON-HEPARINOID) · THROMBOSIS WITH HEPARIN-INDUCED THROMBOCYTOPENIA DURING PERCUTANEOUS CORONARY INTERVENTION ·+2
SANDOZ
BIVALIRUDIN
THROMBIN INHIBITORS (NON-HEPARINOID) · THROMBOSIS WITH HEPARIN-INDUCED THROMBOCYTOPENIA DURING PERCUTANEOUS CORONARY INTERVENTION ·+2
FRESENIUS KABI
BIVALIRUDIN
THROMBIN INHIBITORS (NON-HEPARINOID) · THROMBOSIS WITH HEPARIN-INDUCED THROMBOCYTOPENIA DURING PERCUTANEOUS CORONARY INTERVENTION ·+2
DR.REDDY'S LAB
BIVALIRUDIN
THROMBIN INHIBITORS (NON-HEPARINOID) · THROMBOSIS WITH HEPARIN-INDUCED THROMBOCYTOPENIA DURING PERCUTANEOUS CORONARY INTERVENTION ·+2
APOTEX CORP
ARGATROBAN
THROMBIN INHIBITORS (NON-HEPARINOID) · THROMBOSIS IN HEPARIN-INDUCED THROMBOCYTOPENIA ·+2
MYLAN INSTITUTI
ARGATROBAN
THROMBIN INHIBITORS (NON-HEPARINOID) · THROMBOSIS IN HEPARIN-INDUCED THROMBOCYTOPENIA ·+2
WEST-WARD,INC./
BIVALIRUDIN
THROMBIN INHIBITORS (NON-HEPARINOID) · THROMBOSIS WITH HEPARIN-INDUCED THROMBOCYTOPENIA DURING PERCUTANEOUS CORONARY INTERVENTION ·+2
FRESENIUS KABI
Filter & compare in the drug finder →
Opens the drug finder with Thrombin Inhibitors (Non-Heparinoid) preselected. Add indication or manufacturer filters there.
Thrombin inhibitors (non-heparinoid), more formally known as direct thrombin inhibitors (DTIs), are an anticoagulant drug class distinct from heparin and heparinoids because they do not rely on endogenous antithrombin to exert their activity.
These agents—including parenteral drugs such as argatroban and bivalirudin, as well as the oral agent dabigatran—bind directly and reversibly to the active site or exosite of both circulating and clot-bound thrombin, thereby preventing the conversion of fibrinogen to fibrin and inhibiting thrombin-induced platelet activation.
Clinically, this class serves as an essential therapy for managing thromboembolism in patients with heparin-induced thrombocytopenia, providing procedural anticoagulation during percutaneous coronary intervention, and reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation or deep vein thrombosis.
-
clevelandclinic.org
Thrombin inhibitors (non-heparinoid), more formally known as direct thrombin inhibitors (DTIs), are an anticoagulant drug class distinct from heparin and heparinoids because they do not rely on endogenous antithrombin to exert their activity
-
nih.gov
Thrombin inhibitors (non-heparinoid), more formally known as direct thrombin inhibitors (DTIs), are an anticoagulant drug class distinct from heparin and heparinoids because they do not rely on endogenous antithrombin to exert their activity
-
alodokter.com
These agents—including parenteral drugs such as argatroban and bivalirudin, as well as the oral agent dabigatran—bind directly and reversibly to the active site or exosite of both circulating and clot-bound thrombin, thereby preventing the conversion of fibrinogen to fibrin and inhibiting thrombin-induced platelet activation
-
nih.gov
These agents—including parenteral drugs such as argatroban and bivalirudin, as well as the oral agent dabigatran—bind directly and reversibly to the active site or exosite of both circulating and clot-bound thrombin, thereby preventing the conversion of fibrinogen to fibrin and inhibiting thrombin-induced platelet activation
-
mlo-online.com
These agents—including parenteral drugs such as argatroban and bivalirudin, as well as the oral agent dabigatran—bind directly and reversibly to the active site or exosite of both circulating and clot-bound thrombin, thereby preventing the conversion of fibrinogen to fibrin and inhibiting thrombin-induced platelet activation Clinically, this class serves as an essential therapy for managing thromboembolism in patients with heparin-induced thrombocytopenia, providing procedural anticoagulation du...
-
nih.gov
Clinically, this class serves as an essential therapy for managing thromboembolism in patients with heparin-induced thrombocytopenia, providing procedural anticoagulation during percutaneous coronary intervention, and reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation or deep vein thrombosis
-
wikipedia.org
Clinically, this class serves as an essential therapy for managing thromboembolism in patients with heparin-induced thrombocytopenia, providing procedural anticoagulation during percutaneous coronary intervention, and reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation or deep vein thrombosis
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.